Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of sexual function in sexually active men treated for benign prostatic hyperplasia
2012-002047-26Phase 4Completed
- Sponsor
- GSK
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of alpha blocker + 5-alpha reductase inhibitor in benign prostatic hyperplasia (BPH) (2 arms), sponsored by GSK. Primary endpoint: MSHQ total score change. Started Aug 2012; status: completed.
02
Drugs
alpha blocker + 5-alpha reductase inhibitor
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2012-002047-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002047-26.